Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2001 in healthy subjects
NCT05942612Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2023
- Primary completion
- Nov 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR-2001 in systemic lupus erythematosus (SLE) (12 cohorts), sponsored by Hengrui Therapeutics. Primary endpoint: Adverse events. Started Jul 2023; status: completed.
02
Drugs
SHR-2001
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05942612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05942612.